• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

西班牙的经济激励措施以及体外冲击波碎石机和直线加速器的分布情况。

Economic incentives and the distribution of extracorporeal shock wave lithotripters and linear accelerators in Spain.

作者信息

Lázaro P, Fitch K

机构信息

Instituto de Salud Carlos III.

出版信息

Int J Technol Assess Health Care. 1996 Fall;12(4):735-44. doi: 10.1017/s0266462300011016.

DOI:10.1017/s0266462300011016
PMID:9136480
Abstract

We studied the role of economic incentives for private providers in explaining Spain's disproportionately large number of extracorporeal shock wave lithotripters (ESWLs) and low number of linear accelerators (linacs) per million population (pmp) in comparison to other countries of the Organization for Economic Cooperation and Development (OECD). We found that the reimbursement policy for 1990 allowed an average profit per private ESWL of $732,000, but no profit for linacs. Regional per-capita income was positively correlated with ESWLs pmp in Spain (R2 = 0.49; p = .001), but not with linacs. Sixty-nine percent of ESWLs were privately held versus only 16% of linacs. To avoid these types of distortions, financial incentives should be based on a reasonable relationship between cost and charges and should be associated with the appropriateness of medical care.

摘要

我们研究了经济激励措施对私人医疗服务提供者的作用,以解释西班牙与经济合作与发展组织(经合组织)其他国家相比,每百万人口(pmp)体外冲击波碎石机(ESWL)数量过多而直线加速器(直线加速器)数量过少的原因。我们发现,1990年的报销政策允许每台私人ESWL平均盈利73.2万美元,但直线加速器无盈利。西班牙的地区人均收入与每百万人口的ESWL数量呈正相关(R2 = 0.49;p = 0.001),但与直线加速器数量无关。69%的ESWL是私人拥有的,而直线加速器只有16%。为避免这类扭曲现象,经济激励措施应基于成本与收费之间的合理关系,并应与医疗服务的适当性相关联。

相似文献

1
Economic incentives and the distribution of extracorporeal shock wave lithotripters and linear accelerators in Spain.西班牙的经济激励措施以及体外冲击波碎石机和直线加速器的分布情况。
Int J Technol Assess Health Care. 1996 Fall;12(4):735-44. doi: 10.1017/s0266462300011016.
2
The distribution of "big ticket" medical technologies in OECD countries. Organization for Economic Cooperation and Development.经合组织国家“大额”医疗技术的分布情况。经济合作与发展组织。
Int J Technol Assess Health Care. 1995 Summer;11(3):552-70. doi: 10.1017/s0266462300008722.
3
Abruptly changing patterns of diffusion and use of extracorporeal shock-wave renal lithotripsy.体外冲击波肾碎石术的扩散和使用模式突然改变。
Am J Kidney Dis. 1991 Jul;18(1):103-7. doi: 10.1016/s0272-6386(12)80298-8.
4
Accounting for complexity: aligning current payment models with the breadth of care by different specialties.考虑复杂性:使当前支付模式与不同专科的广泛医疗服务相匹配。
Am Fam Physician. 2014 Dec 1;90(11):790.
5
Cost-effectiveness of extracorporeal shock-wave lithotripsy versus cholecystectomy for symptomatic gallstones.体外冲击波碎石术与胆囊切除术治疗有症状胆结石的成本效益分析
Gastroenterology. 1991 Jul;101(1):189-99. doi: 10.1016/0016-5085(91)90477-3.
6
Variations in Patterns of Utilization and Charges for the Care of Headache in North Carolina, 2000-2009: A Statewide Claims' Data Analysis.2000 - 2009年北卡罗来纳州头痛治疗的使用模式和费用变化:一项全州索赔数据分析
J Manipulative Physiol Ther. 2016 May;39(4):229-39. doi: 10.1016/j.jmpt.2016.02.008.
7
Economic evaluation of extracorporeal shock wave lithotripsy, percutaneous ultrasonic lithotripsy, and standard surgical treatment of urolithiasis--a Canadian perspective.体外冲击波碎石术、经皮超声碎石术及尿石症标准外科治疗的经济学评估——加拿大视角
Clin Invest Med. 1987 Mar;10(2):86-95.
8
Cost analysis of extracorporeal shock wave lithotripsy relative to other surgical and nonsurgical treatment alternatives for urolithiasis.
Med Care. 1986 Dec;24(12):1151-60. doi: 10.1097/00005650-198612000-00007.
9
Impact of the limited generalist (no hospital, no procedures) model on the viability of family practice training.有限全科医生(无医院、无诊疗操作)模式对家庭医学培训可行性的影响。
J Am Board Fam Pract. 2002 May-Jun;15(3):191-200.
10
Access to biologicals in Crohn's disease in ten European countries.十个欧洲国家克罗恩病生物制剂的可及性。
World J Gastroenterol. 2017 Sep 14;23(34):6294-6305. doi: 10.3748/wjg.v23.i34.6294.